Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.

导出 LinkOut

翻译打印收藏纠错

作者： P,Smyth ^[1] ; L,Ferguson ^[2] ; J F,Burrows ^[3] ; R E,Burden ^[3] ; S R,Tracey ^[1] ; Ú M,Herron ^[1] ; M,Kovaleva ^[2] ; R,Williams ^[1] ; A J,Porter ^[2] ; D B,Longley ^[4] ; C J,Barelle ^[1] ; C J,Scott ^[2]

作者单位： Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom. ^[1] Elasmogen Ltd., Aberdeen, United Kingdom. ^[2] School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom. ^[3] Scottish Biologics Facility, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom. ^[4]

关键词 cancer cathepsin inhibitor therapeutic vNAR

DOI 10.3389/fphar.2023.1296567

PMID 38116078

发布时间 2023-12-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2023年14卷

1296567页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除